Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Predictive Impact of PD-L1 expression for anti-tumor activity of osimertinib in patients with T790M mutated non-small cell lung cancer

Next Previous
X
Search
Trial Profile

Predictive Impact of PD-L1 expression for anti-tumor activity of osimertinib in patients with T790M mutated non-small cell lung cancer

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 02 Apr 2020 Status changed from active, no longer recruiting to discontinued.
    • 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
    • 24 Apr 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top